[Statins and stroke].
The role of cholesterol in the pathogenesis of stroke, the role of the treatment of hypercholesterolemia in the prevention of stroke have been controversed. The explanation was based on the heterogenous characteristics of stroke, on the relationship between several risk factors, and on the role of the age, in the evaluation of these 2 questions. The discovery of statins induced major therapeutic trials whose aim was the impact on coronary events. These trials demonstrated that statins were accompanied with a major reduction of cholesterol levels and stroke events similar to the one observed with coronary events. Even prospective, placebo controlled, randomized specific trials for stroke are necessary, we can state that cholesterol reduction is the most important mechanism accounting for a decrease in stroke occurrence with statins.
Unité d'Urgence Cérébro-Vasculaire, Service de Neurologie, CHU, 3, rue du Faubourg Raines, 21000 Dijon.
G V
GV
Osseby
E
E
Manceau
M
M
Lemesle-Martin
V
V
Thomas
M
M
Giroud
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000627:therapeutic use*; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000517:prevention & control*
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008148:Lovastatin